Safety, tolerability, pharmacokinetics, and pharmacodynamics of HBM9161, a novel FcRn inhibitor, in a phase I study for healthy Chinese volunteers

• Auteurs principaux: Desmond Y. H. Yap (Auteur), Jojo Hai (Auteur), Paul C. H. Lee (Auteur), Xueying Zhou (Auteur), Michael Lee (Auteur), Yu Zhang (Auteur), Meng Wang (Auteur), Xiaoxiang Chen (Auteur)
• Format: Livre
• Publié: Wiley, 2021-09-01T00:00:00Z.
• Sujets: article
• Accès en ligne: Connect to this object online.

Abstract Blockade of the binding between neonatal Fc receptor and IgG‐Fc reduces circulating IgG, and thus emerges as a potential therapy for IgG‐mediated autoimmune conditions. This was a double blind, randomized, single ascending dose study to evaluate the safety, pharmacokinetics, and pharmacodyn...